Payment overview · 2025
General Payments
$518.84
26 reported records · 4 companies
Healthcare provider profile · identity verified
Michael Burch, MD
Allopathic & Osteopathic Physicians|Hospitalist · BESSEMER, AL · NPI 1831148337
Verified facts
What the public records show
CMS Open Payments records show Michael Burch, MD received $518.84 in general payments during 2025 across 26 reported records.
ABBVIE INC. accounted for 40.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 701 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $210.59 | 40.6% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $159.37 | 30.7% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $106.22 | 20.5% | 5 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $42.66 | 8.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $518.84 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $210.59 | 11 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $180.90 | 8 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $160.78 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $159.37 | 8 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $159.37 | 8 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $111.59 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $106.22 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $88.97 | 4 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $42.66 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 701 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
52 | 52 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
701 | 49 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1554 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1484 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 1217 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1065 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 968 | 48 |
| Trazodone Hcl | Trazodone Hcl | 869 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 719 | 45 |
| Eliquis | Apixaban | 701 | 49 |
| Mirtazapine | Mirtazapine | 673 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 614 | 41 |
| Donepezil Hcl | Donepezil Hcl | 608 | 39 |
| Potassium Chloride | Potassium Chloride | 591 | 50 |
| Losartan Potassium | Losartan Potassium | 574 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 572 | 51 |
| Sertraline Hcl | Sertraline Hcl | 527 | 33 |
| Memantine Hcl | Memantine Hcl | 514 | 28 |
| Omeprazole | Omeprazole | 490 | 24 |
| Metformin Hcl | Metformin Hcl | 433 | 21 |
| Famotidine | Famotidine | 430 | 23 |
| Buspirone Hcl | Buspirone Hcl | 427 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 413 | 20 |
| Lisinopril | Lisinopril | 410 | 27 |
| Furosemide | Furosemide | 382 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 378 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 375 | 31 |
| Levetiracetam | Levetiracetam | 343 | 24 |
| Simvastatin | Simvastatin | 337 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 329 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 307 | 17 |
| Carvedilol | Carvedilol | 277 | 27 |
| Myrbetriq | Mirabegron | 271 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 262 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 252 | 17 |
| Divalproex Sodium | Divalproex Sodium | 244 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 207 | 17 |
| Montelukast Sodium | Montelukast Sodium | 202 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 201 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 201 | 74 |
| Ezetimibe | Ezetimibe | 197 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 196 | suppressed |
| Spironolactone | Spironolactone | 175 | suppressed |
| Gabapentin | Gabapentin | 170 | 44 |
| Olanzapine | Olanzapine | 165 | 17 |
| Sucralfate | Sucralfate | 162 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 156 | suppressed |
| Xarelto | Rivaroxaban | 139 | suppressed |
| Clonazepam | Clonazepam | 134 | 25 |
| Aripiprazole | Aripiprazole | 133 | suppressed |
| Allopurinol | Allopurinol | 132 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 131 | suppressed |
| Valsartan | Valsartan | 131 | suppressed |
| Tradjenta | Linagliptin | 130 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 128 | 19 |
| Propranolol Hcl | Propranolol Hcl | 121 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 120 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 117 | 11 |
| Baclofen | Baclofen | 117 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 109 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 107 | suppressed |
| Lorazepam | Lorazepam | 106 | 39 |
| Glimepiride | Glimepiride | 100 | suppressed |
| Januvia | Sitagliptin Phosphate | 100 | suppressed |
| Alprazolam | Alprazolam | 91 | 15 |
| Risperidone | Risperidone | 88 | suppressed |
| Methocarbamol | Methocarbamol | 84 | 19 |
| Venlafaxine Hcl | Venlafaxine Hcl | 84 | suppressed |
| Rexulti | Brexpiprazole | 81 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 80 | suppressed |
| Meloxicam | Meloxicam | 79 | suppressed |
| Atenolol | Atenolol | 77 | suppressed |
| Celecoxib | Celecoxib | 76 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 76 | suppressed |
| Cilostazol | Cilostazol | 75 | suppressed |
| Ondansetron Odt | Ondansetron | 74 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 74 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 73 | suppressed |
| Jardiance | Empagliflozin | 71 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 67 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 67 | 23 |
| Prednisone | Prednisone | 64 | suppressed |
| Digoxin | Digoxin | 63 | suppressed |
| Latanoprost | Latanoprost | 63 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | suppressed |
| Carbamazepine | Carbamazepine | 61 | suppressed |
| Bumetanide | Bumetanide | 60 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 60 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 22 |
| Memantine Hcl Er | Memantine Hcl | 58 | suppressed |
| Xifaxan | Rifaximin | 56 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 53 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 53 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 53 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 53 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | suppressed |
| Nadolol | Nadolol | 53 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 53 | suppressed |
| Primidone | Primidone | 53 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 53 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 53 | suppressed |
| Trospium Chloride | Trospium Chloride | 53 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 52 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 19 |
| Metoclopramide Hcl | Metoclopramide Hcl | 52 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | 27 |
| Benztropine Mesylate | Benztropine Mesylate | 48 | suppressed |
| Lovastatin | Lovastatin | 45 | suppressed |
| Methimazole | Methimazole | 45 | suppressed |
| Ranolazine Er | Ranolazine | 42 | suppressed |
| Humalog | Insulin Lispro | 41 | suppressed |
| Lacosamide | Lacosamide | 41 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 41 | suppressed |
| Modafinil | Modafinil | 40 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Chlorthalidone | Chlorthalidone | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 30 |
| Rivastigmine | Rivastigmine | 39 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 25 |
| Torsemide | Torsemide | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 15 |
| Budesonide Dr | Budesonide | 34 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 34 | suppressed |
| Lidocaine | Lidocaine | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 31 | suppressed |
| Amantadine | Amantadine Hcl | 29 | suppressed |
| Cephalexin | Cephalexin | 29 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Gemtesa | Vibegron | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Metronidazole | Metronidazole | 25 | 20 |
| Nystop | Nystatin | 25 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 24 |
| Fluconazole | Fluconazole | 24 | 15 |
| Haloperidol | Haloperidol | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 21 |
| Admelog | Insulin Lispro | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Letrozole | Letrozole | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Levemir | Insulin Detemir | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 19 | 11 |
| Brimonidine Tartrate | Brimonidine Tartrate | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | 11 |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Enbrel | Etanercept | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $518.84 · 26 records | ABBVIE INC. | AVYCAZ, DALVANCE, ELIQUIS, EMBLAVEO, LifeVest, NURTEC ODT, PAXLOVID, TEFLARO, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error